7UM.F · Ultimovacs ASA

-

Please sign in to comment on 7UM.F

1 Comment

Admin

3 years, 7 months ago

Ultimovacs ASA is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Ultimovacs ASA's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 3.1% to $-25M since the same quarter in the previous year.

Finally, its free cash flow grew by 1.1% to $-13M since the same quarter in the previous year.

Based on the above factors, Ultimovacs ASA gets an overall score of 4/5.

Industry	Biotechnology
Sector	Healthcare
ISIN	NO0010851603
CurrencyCode	EUR
Exchange	F

Dividend Yield	0.0%
Beta	1.43
Target Price	None
PE Ratio	None
Market Cap	394M

ABOUT

Ultimovacs ASA

Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

7UM.F · Ultimovacs ASA

-

Ultimovacs ASA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ultimovacs ASA using a moving average strategy